Other Services

This Service

A database built with INDRA combining content from numerous readers and databases. This page allows you to curate the loaded statements. For more information please see the manual.

This Project

INDRA is developed by indralabs, a part of the Harvard Medical School Laboratory of Systems Pharmacology.

This project, indra_db, is also developed by the indralab team. For more information on how we procure our sources, you can go here. This work was funded by ARO grant W911NF‐15‐1‐0544 under the DARPA Communicating with Computers program.

IndraLab

Statements

ZUP1 activates removal processing Ub polyubiquitin chains. 1 / 1

| 1

➶

eidos

"Additionally , they are more potent than the abovementioned Leucettamol A ( Fig. 5 ) .424 CC0651 , a small-molecule selective allosteric site inhibitor of the E2 enzyme hCdc34 , can block the ubiquitination and degradation of p27 and then inhibit tumor cell proliferation ( Fig. 5 ) .425 In addition , small-molecule microarray-based screening has also been successfully used to identify the inhibitor of the SUMO E2 enzyme Ubc9 , and a few small-molecule inhibitors have been found.426 Targeting DUB activity As mentioned , ubiquitination is a dynamic and reversible process , and DUBs mediate the removal and processing of Ub or polyubiquitin chains from ubiquitinated proteins ."

32140262

Our Sources:

INDRA allows us to combine the results from a multitude of sources. In particular, the INDRA Database draws on the following...